Compare Dyne Therapeutics Inc. Common Stock (DYN) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs VNET Group Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while VNET Group Inc trades at $4.54 (market cap $1.49B). The key difference: Dyne Therapeutics Inc. Common Stock is the larger of the two by market cap, and VNET Group Inc is more actively traded (3,619,133 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and VNET Group Inc for 16 Days on average.
| DYN | VNET | |
|---|---|---|
Market Cap | $2.86B | $1.49B |
Volume | 3,341,579 | 3,619,133 |
Sector | Health | Technology |
52-Week High | $26.78 | $14.03 |
52-Week Low | $14.60 | $4.49 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $2.18B | $5.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
VNET trades at $5.26, down 1.13% today, and has hit new 52-week lows recently. The technical outlook is bearish, with moving averages signaling a downtrend. Fundamentally, the company reported a net loss of $256.77 million in 2025, with a negative net income margin of -22.18%, though revenue grew to $9.95 billion. Recent news includes a strategic investment closing and a cooperation agreement with CATL, providing some positive catalysts amid financial challenges.
The outlook remains cautious due to persistent losses and high leverage, but analyst sentiment is moderately positive with a 'Buy' consensus. Key risks include balance sheet strain and competitive pressures in the data center market. Investment opportunity hinges on execution of growth initiatives and improvement in profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
